World experts and funders set priorities for COVID-19 research
Leading health experts from around the world have been meeting at the World Health Organization’s Geneva headquarters to assess the current level of knowledge about the new COVID-19 disease, identify gaps and work together to accelerate and fund priority research needed to help stop this outbreak and prepare for any future outbreaks.
The 2-day forum was convened in line with the WHO R&D Blueprint – a strategy for developing drugs and vaccines before epidemics, and accelerating research and development while they are occurring.
The meeting, hosted in collaboration with GloPID-R (the Global Research Collaboration for Infectious Disease Preparedness) brought together major research funders and over 300 scientists and researchers from a large variety of disciplines.
They discussed all aspects of the outbreak and ways to control it including:
• the natural history of the virus, its transmission and diagnosis;
• animal and environmental research on the origin of the virus, including management measures at the human-animal interface;
• epidemiological studies;
• clinical characterization and management of disease caused by the virus;
• infection prevention and control, including best ways to protect health care workers;
• research and development for candidate therapeutics and vaccines;
• ethical considerations for research;
• and integration of social sciences into the outbreak response.
During the meeting, the more than 300 scientists and researchers participating both in person and virtually agreed on a set of global research priorities. They also outlined mechanisms for continuing scientific interactions and collaborations beyond the meeting which will be coordinated and facilitated by WHO. They worked with research funders to determine how necessary resources can be mobilized so that critical research can start immediately.
The deliberations will form the basis of a research and innovation roadmap charting all the research needed and this will be used by researchers and funders to accelerate the research response.